RxDoctor Payments Data

Richard Uy, MD

Hospitalist · Evansville, INNPI 1841647260

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Johnson & Johnson at 58.1% of the total. Reporting peaked in 2023 at $272 and has fallen 78.3% since, to $59 in 2025. Among hospitalist clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,002in general payments, 2019–2025

Across 63 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$582
  • AbbVie$101
  • Merck$86
  • Pfizer$81
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$66
  • E.r. Squibb & Sons, L.L.C.$53
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$1,002100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,002 in reported general payments places this provider in the 90th percentile of 423 hospitalist providers in Indiana.

See all hospitalist providers in Indiana

Medicare billing

Part B allowed, 2024
$89,718
Medicare patients
287
Services billed
917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$16,153
XareltoRivaroxaban12$6,876
BrilintaTicagrelor15$6,524
CefuroximeCefuroxime Axetil28$234
Metoprolol Succinate29$205
Pantoprazole Sodium29$195
Atorvastatin Calcium50$178
ClopidogrelClopidogrel Bisulfate32$107
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$87
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$73
Carvedilol11$62
Lisinopril19$47
Losartan Potassium14$45
Prednisone16$28
Furosemide15$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$81$16,15322 claims
Johnson & JohnsonXarelto$582$6,87612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 423 hospitalist providers in Indiana.

Other hospitalist in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →